Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies

BACKGROUND: The studies IMvigor 210 cohort 2 and IMvigor211 evaluated the efficacy of atezolizumab in patients with locally advanced or metastatic urothelial cancer (mUC) upon progression to platinum-based chemotherapy worldwide. Yet, the real impact of this drug in specific geographical regions is...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clin Transl Oncol
Egile Nagusiak: Sotelo, M., Alonso-Gordoa, T., Gajate, P., Gallardo, E., Morales-Barrera, R., Pérez-Gracia, J. L., Puente, J., Sánchez, P., Castellano, D., Durán, I.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer International Publishing 2020
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7979625/
https://ncbi.nlm.nih.gov/pubmed/32897497
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12094-020-02482-9
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak